Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

被引：0
|
作者：
Konstantin Huhn
Antonios Bayas
Sebastian Doerck
Benedikt Frank
Kathrin Gerbershagen
Kerstin Hellwig
Boris Kallmann
Christoph Kleinschnitz
Ingo Kleiter
De-Hyung Lee
Volker Limmroth
Mathias Mäurer
Sven Meuth
Peter Rieckmann
Tobias Ruck
Ralf Gold
Ralf A. Linker
机构：
[1] Friedrich-Alexander-University,Department of Neurology, University Hospital Erlangen
[2] Klinikum Augsburg,Department of Neurology
[3] Julius-Maximilians-University Würzburg,Department of Neurology
[4] University Hospital Essen,Department of Neurology
[5] Klinikum Köln-Merheim,Department of Neurology
[6] St. Josef-Hospital/Ruhr-University Bochum,Department of Neurology
[7] MS Center Bamberg,Department of Neurology
[8] Caritas Krankenhaus Bad Mergentheim,Department of Translational Neurology
[9] University Hospital Münster,Department of Neurology
[10] Julius-Spital Würzburg,undefined
[11] Marianne-Strauß-Klinik,undefined
[12] Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH,undefined
[13] Medical Park Klinik Loipl,undefined
来源：
Journal of Neurology | 2018年 / 265卷
关键词：
Alemtuzumab; Fingolimod; Multiple sclerosis; Disease-modifying treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1521 / 1527
页数：6
相关论文
共 50 条
  • [21] Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study
    Emmanuelle Le Page
    Véronique Deburghgraeve
    Marie-Antoinette Lester
    Isabelle Cardiet
    Emmanuelle Leray
    Gilles Edan
    Journal of Neurology, 2015, 262 : 1024 - 1034
  • [22] Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study
    Hernandez-Preciado, Martha Rocio
    Marquez-Pedroza, Jazmin
    Sanchez-Rosales, Nayeli Alejandra
    Garcia-Rivera, Jose de Jesus
    Kobayashi-Gutierrez, Antonio
    Torres-Mendoza, Blanca Miriam
    Chavarria-Avila, Efrain
    Montano-Serrano, Raul Alejandro
    Cortes-Enriquez, Fernando
    Mireles-Ramirez, Mario Alberto
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [23] Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta
    Correale, J
    Rush, C
    Amengual, A
    Goicochea, MT
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 154 (1-2) : 215 - 215
  • [24] The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
    Izquierdo, Guillermo
    Damas, Fatima
    Dolores Paramo, Maria
    Luis Ruiz-Pena, Juan
    Navarro, Guillermo
    PLOS ONE, 2017, 12 (04):
  • [25] EVALUATING PATIENT ADHERENCE RATES TO APPROVED DISEASE MODIFYING THERAPIES (DMT) FOR RELAPSING-REMITTING MS (RRMS): OPERATIONAL SETUP FOR A MULTI-COUNTRY, MULTI-CENTER STUDY
    de Scheffer, Apecechea M.
    Faber, S.
    Potthoff, P.
    Eichmann, F.
    VALUE IN HEALTH, 2013, 16 (07) : A626 - A627
  • [26] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [27] Analysis of first line therapy criteria responses in a cohort of 1300 relapsing remitting ms patients
    Labauge, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 260 - 260
  • [28] Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study
    Saito, Tomoyuki
    Ohmura, Hirotoshi
    Nojiri, Shuko
    Daida, Hiroyuki
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2020, 6 (01)
  • [29] Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study
    Tomoyuki Saito
    Hirotoshi Ohmura
    Shuko Nojiri
    Hiroyuki Daida
    Journal of Pharmaceutical Health Care and Sciences, 6
  • [30] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy
    Confavreux, C.
    Twyman, C. L.
    Arnold, D.
    Cohen, J.
    Coles, A. J.
    Fox, E. J.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 88 - 88
12345